

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or other independent financial adviser duly authorised under the Financial Services and Markets Act 2000, if you are in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser.

If you have sold or otherwise transferred all of your iSOFT Shares and/or your Torex Shares (as the case may be), please forward this document at once, to the purchaser or transferee or to the bank, stockbroker, or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee. However, this document should not be forwarded or transmitted in or into the United States, Canada, Australia or Japan or such other jurisdictions where to do so would constitute a violation of the relevant laws of such jurisdiction. The distribution of this document in jurisdictions other than the UK may be restricted by law and therefore persons into whose possession this document comes should inform themselves about and observe such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

Applications have been made to the UK Listing Authority for the New iSOFT Shares to be admitted to the Official List and to the London Stock Exchange for such shares to be admitted to trading on its market for listed securities. It is expected that admission of the New iSOFT Shares to the Official List will become effective and that dealings on the London Stock Exchange (for normal settlement) will commence at 8.00 am (London time) on the first business date after the date on which the Merger Offer becomes or is declared unconditional in all respects (save only for any condition relating to Admission).

Supplementary listing particulars relating to the issue of
up to 102,721,328

ordinary shares of 10 pence each in



iSOFT Group plc

3716736

in connection with its recommended merger with

Torex PLC

1007428

The information contained in this document is supplemental to and should be read in conjunction with the listing particulars relating to iSOFT Group plc and the New iSOFT Ordinary Shares dated 13 November 2003 (the "Listing Particulars"). The definitions contained in the Listing Particulars also apply in these supplementary listing particulars.

A copy of this document, which comprises supplementary listing particulars relating to iSOFT prepared in accordance with the Listing Rules made under section 74 of the Financial Services and Markets Act 2000, has been delivered to the Registrar of Companies in England and Wales for registration in accordance with section 83 of that Act.

Hoare Govett Limited, which is regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for iSOFT and no one else in connection with the Merger Offer and will not be responsible to anyone other than iSOFT for providing the protections afforded to clients of Hoare Govett Limited or for providing advice in relation to the Merger Offer.

The Merger Offer is not being made, directly or indirectly, in or into, or by the use of mails or any means or instrumentality (including, without limitation, telephonically or electronically) of interstate or foreign commerce of, or any facility of a national securities exchange of, the United States, Canada, Australia or Japan and the Merger Offer will not be capable of acceptance by any such use, means, instrumentality or facilities from or within the United States, Canada, Australia or Japan. Accordingly, copies of this document and any related documents are not being, and must not be, in whole or in part, directly or indirectly, mailed or otherwise forwarded, distributed or sent in or into or from the United States, Canada, Australia or Japan and persons receiving this document and any related document (including, without limitation, custodians, nominees and trustees) must not mail or otherwise forward, distribute or send them, in whole or in part, in or into or from the United States, Canada, Australia or Japan or such other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

The availability of the Merger Offer to persons who are not resident in the United Kingdom may be affected by the laws of the relevant jurisdictions. Persons who are not resident in the United Kingdom should inform themselves about and observe any applicable requirements.

US Shareholders of Torex are excluded from participating in the Merger Offer. iSOFT reserves the right, however, to include US Shareholders in the Merger Offer. In such event, the New iSOFT Shares will be offered to US Shareholders of Torex in reliance upon an exemption from registration under the US Securities Act.

The New iSOFT Shares have not been, nor will they be, registered under the US Securities Act or under any of the relevant securities laws of any state of the United States or of Canada, Australia or Japan. Accordingly, the New iSOFT Shares may not (unless an exemption under relevant securities laws is applicable) be offered, sold, resold or delivered, directly or indirectly, in or into the United States, Canada, Australia or Japan or for the account or benefit of any person located in Canada, Australia or Japan or any US Person.

CONTENTS

	<i>Page</i>
Part I New matters	3
Part II Additional information	4

**This document is for information purposes only.
You are not required to take any action.**

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

<i>Event</i>	<i>Time and date</i>
First closing date of the Merger Offer	3.00 pm on 4 December 2003
Latest time and date for receipt of forms of proxy for the iSOFT Extraordinary General Meeting	3.00 pm on 7 December 2003
iSOFT Extraordinary General Meeting	3.00 pm on 9 December 2003

Part I

New matters

iSOFT and Torex made announcements on 19 November 2003 and 25 November 2003 in connection with the Merger Offer.

The iSOFT Directors, the Proposed Directors and the Torex Directors consider it appropriate to provide the new information, contained in this Part I, to both iSOFT and Torex Shareholders in the context of the Merger Offer in order to ensure that they have the most up to date information relating to iSOFT and Torex available to them.

The following is the full text of the announcement made by iSOFT and Torex on 19 November 2003.

"iSOFT Group plc ("iSOFT") and Torex PLC ("Torex") (together the "Companies")

Response to IBA Health Limited Announcement

Further to an announcement on 19 November 2003 to the Australian Stock Exchange by IBA Health Limited ("IBA"), a company incorporated in Australia, the Companies confirm that they have been put on notice by IBA that it proposes to apply to the Competition Appeal Tribunal for a review of the OFT decision of 7 November 2003 not to refer the merger of the Companies to the Competition Commission. The announcement states that IBA intends to lodge its application with the Tribunal within the next 7 days.

The Companies understand that the basis of the appeal is the belief of IBA that there are material errors of fact and law in the OFT decision. Both Companies consider there to be no merit whatsoever in this belief and will intervene to vigorously support the OFT decision. In addition, the Companies will deal with the appeal in such a way as to avoid any impact on the timetable of the merger, the first closing date of which is Thursday 4 December 2003."

The following is the full text of the announcement made by iSOFT and Torex on 25 November 2003.

"iSOFT Group plc ("iSOFT") and Torex PLC ("Torex") (together the "Companies")

Competition Appeal Tribunal

On 19 November 2003, the Companies announced that they had been put on notice by IBA Health Limited that it proposed to apply to the Competition Appeal Tribunal for a review of the OFT decision of 7 November 2003 not to refer the merger of the Companies to the Competition Commission. The Companies have now been served with the application and been informed that the Competition Appeal Tribunal is to hear the matter on 28 November 2003.

As stated in their announcement on 19 November, both Companies consider there to be no merit whatsoever in the application. They have been granted permission to intervene and accordingly, the Companies will intervene to vigorously support the OFT decision."

Part II

Additional information

1. Responsibility statement

- (a) The iSOFT Directors and the Proposed Directors, whose names appear in paragraphs 2(a) and 2(b) below, accept responsibility for the information contained in this document other than for that relating to the Torex Group and the Torex Directors. To the best of the knowledge and belief of the iSOFT Directors and the Proposed Directors (who have taken all reasonable care to ensure that such is the case) the information contained in this document for which they are responsible is in accordance with the facts and does not omit anything likely to affect the import of such information.
- (b) The Torex Directors, whose names are set out in paragraph 2(c) below, accept responsibility for the information contained in this document relating to the Torex Group and the Torex Directors. To the best of the knowledge and belief of the Torex Directors (who have taken all reasonable care to ensure that such is the case) the information contained in this document for which they are responsible is in accordance with the facts and does not omit anything likely to affect the import of such information.

2. Directors

- (a) The full names of the iSOFT Directors and their respective functions are:

<i>Name</i>	<i>Function</i>
Roger Joseph Dickens	Executive Chairman
Patrick Cryne	Chief Executive Officer
Timothy Andrew Whiston	Group Finance Director
Stephen Paul Graham	Chief Operating Officer
Digby Marritt Jones	Senior Non-Executive Director
Eurfyl ap Gwilym	Non-Executive Director
Geoffrey Charles White	Non-Executive Director
Rene Kern	Non-Executive Director

The current business address of each of the iSOFT Directors is at Bridgewater House, 58-60 Whitworth Street, Manchester, Lancashire M1 6LT save for Digby Jones whose business address is CBI, Centre Point, 103 New Oxford Street, London WC1A 1DU, Geoff White whose business address is 8 Rawlings Street, Chelsea, London SW3 2LS, Eurfyl ap Gwilym whose business address is 12 Ty Draw Street Road, Cardiff CF23 5HA and Rene Kern whose business address is General Atlantic Partners, 3 Pickwick Plaza, Greenwich, USA CT06830.

- (b) The full names of the Proposed Directors and their proposed respective functions following the Merger are:

<i>Name</i>	<i>Proposed function</i>
Christopher Edward Moore	Chief Executive Officer
Mark Gavin Woodbridge	Business Development Director
Dr Colin David Wall	Non Executive Director
David Allan Thorpe	Non Executive Director

The current business address of each Proposed Director is Torex House, Daventry Road, Banbury, Oxfordshire OX16 3ST.

- (c) The Torex Directors and their respective functions within Torex are:

<i>Name</i>	<i>Function</i>
Christopher Edward Moore	Executive Chairman
Mark Chalice Pearman	Business Development Director
Mark Gavin Woodbridge	Financial Director
Stephen John Garrington	Chief Executive — Health
Dr Colin David Wall	Non Executive Director
Nigel Edward Leavy	Non Executive Director
David Allan Thorpe	Non Executive Director

The business address of each Torex Director is Torex House, Daventry Road, Banbury, Oxfordshire OX16 3ST.

3. No significant change

Save as disclosed in this document there has been no significant change and no significant new matter has arisen since the publication of the Listing Particulars.

4. Documents available for inspection

Copies of the documents referred to in paragraph 16 of Part V of the Listing Particulars, the announcement released by IBA Health Limited on 19 November 2003 to the Australian Stock Exchange, IBA's application to the Competition Appeal Tribunal and this document may be inspected free of charge at the offices of Ashurst Morris Crisp, Broadwalk House, 5 Appold Street, London EC2A 2HA during normal business hours on any weekday (Saturdays, Sundays and public holidays excepted) up to and including the later of the date which is 14 days from the date of this document, or until the Extraordinary General Meeting or, until the end of the Offer Period.

25 November 2003

